1Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of Ebi3 and P28 protein, induce proliferration of naive CD4^+ T cells. Immunity, 2002, 16(6) :779
2Spercher CA, Sprecher CA, Grant FJ, et al. Cloning and characterization of a novel class Ⅰ cytokine receptor. Bicchem Biophy Res Commun, 1998, 246(1):82
3Chen Q, Ghilardi N, Wang H, et al. Development of Th1-type immune responses requires the type Ⅰ cytokine receptor TCCR. Nature, 2000, 407(16806) :916
4Poleganov MA, Bachmann M, Pfeilschifter J, et al. Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappa B binding sites in the human EBI3 promotor. Mol Immunol, 2008, 45(10) :2869
5Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol, 1996, 70(2):1143
6Devergne O, Coulomb-L'Hermine A, Capel F, et al. Expression of Epstein Barr virus-induced gene 3, an interleukin-12 p40 related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol, 2001, 159 (5) : 1763
7Schnurr M, Toy T, Shin A, et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in hu man dendritic cells: a novel role for the cAMP pathway. Blood, 2005, 105(4) : 1582
8Wirtz S, Becker C, Fantini MC, et al. EBV induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF- kappa B activation. J Immunol, 2005, 174(5):2814
9Maaser C, Egan LJ, Birkenbach MP, et al. Expression of Epstein-Barr vires-induced gene 3 and other interleuldn-12-related molecules by human intestinal epithelium. Immunology, 2004, 112(3):437
10Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol, 2004, 172(4) :2225
同被引文献12
1Zetterberg E, Lundberg LG, Palmblad J. Expression of cox-2, tie-2and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera [ J ]. Br J Haematol, 2003,121 (3) :497 -499.
2Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic abili- ty and expression of angiogenic cytokines in myeloma : evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression [ J ]. Blood,2004,1 04 (4) : 1159 - 1165.
3Noren-Nystrtim U, Heyman M, Frisk P, et al. Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome[ J]. Br J Haematol,2009 ,146 :521 - 530.
4Antic D, Jovanovic MP, Fekete MD, et al. Assessment of bone mar- row microvessel density in chronic lymphocytic leukemia[J]. Appl Immunohistochem Mol Morpho1,2010,18 (4) :353 - 356.
5Matuszewski L, Persigehl T, Wall A, et al. Assessment of bone mar- row angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron ox- ides : initial experience [J]. Radiology,2007,242 ( 1 ) :217 - 224.
6Alexandrakis MG, Passam FH, Kyriakou DS, et al. Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes [ J ]. J Mol Histol, 2004,35 ( 8 - 9) :857 -863.
7Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders:a study of 115 pa- tients with clinicopathological and molecular cmTelations [ J ]. Br J Haemato1.2008.140 (2) : 162 - 168.
8Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascu- lar endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2- V617F mutational status[J]. Br J Haematol, 2009, 146:150 - 157.
9Ftireder W, Krauth MT, Sperr WR, et al. Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia [ J ]. Am J Pathol, 2006, 168(1) :123 - 130.
10Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcy- tosine, mitoxantrone, and bevacizumab [ J ]. Clin Cancer Res, 2004,10( 11 ) :3577 - 3585.
